Xinyu Jia; Hengrui Zhang; Yuan Ma; Zhenzhen Wu; Ningfei Ji; Mao Huang

doi:10.7555/JBR.34.20200079

Volume 35 Issue 3

May 2021

Turn off MathJax

Article Contents

Article Navigation > The Journal of Biomedical Research > 2021 > 35(3): 247-252

Xinyu Jia, Hengrui Zhang, Yuan Ma, Zhenzhen Wu, Ningfei Ji, Mao Huang. The prognosis and short-term efficacy of corticosteroid therapy for COVID-19 patients[J]. The Journal of Biomedical Research, 2021, 35(3): 247-252. doi: 10.7555/JBR.34.20200079

Citation:

Xinyu Jia, Hengrui Zhang, Yuan Ma, Zhenzhen Wu, Ningfei Ji, Mao Huang. The prognosis and short-term efficacy of corticosteroid therapy for COVID-19 patients[J]. The Journal of Biomedical Research, 2021, 35(3): 247-252. doi: 10.7555/JBR.34.20200079

Citation:

PDF( 1989 KB)

The prognosis and short-term efficacy of corticosteroid therapy for COVID-19 patients

doi: 10.7555/JBR.34.20200079

Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China

More Information

Corresponding author: Tel/Fax: +86-25-68136269/+86-25-83673567, E-mail: huangmao6114@126.com
Received: 2020-05-31
Revised: 2020-06-17
Accepted: 2020-06-19

Published: 2020-08-21

Issue Date: 2021-05-28

Abstract

FullText(HTML)

References(13)

References

[1]	Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome[J]. Am J Respir Crit Care Med, 2018, 197(6): 757–767. doi: 10.1164/rccm.201706-1172OC
[2]	Ni YN, Chen G, Sun JK, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis[J]. Crit Care, 2019, 23(1): 99. doi: 10.1186/s13054-019-2395-8
[3]	Auyeung TW, Lee JSW, Lai WK, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study[J]. J Infect, 2005, 51(2): 98–102. doi: 10.1016/j.jinf.2004.09.008
[4]	Siemieniuk RAC, Meade MO, Alonso-Coello P, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis[J]. Ann Intern Med, 2015, 163(7): 519–528. doi: 10.7326/M15-0715
[5]	Zhao JP, Hu Y, Du RH, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia[J]. Chin J Tubercul Respirat Dis (in Chinese), 2020, 43(3): 183–184.
[6]	Du ZW, Wang L, Cauchemez S, et al. Risk for Transportation of Coronavirus Disease from Wuhan to Other Cities in China[J]. Emerg Infect Dis, 2020, 26(5): 1049–1052. doi: 10.3201/eid2605.200146
[7]	Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497–506. doi: 10.1016/S0140-6736(20)30183-5
[8]	Ruan QR, Yang K, Wang WX, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China[J]. Intensive Care Med, 2020, 46(5): 846–848. doi: 10.1007/s00134-020-05991-x
[9]	Wang DW, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China[J]. Jama, 2020, 323(11): 1061–1069. doi: 10.1001/jama.2020.1585
[10]	Yang XB, Yu Y, Xu JQ, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8(5): 475–481. doi: 10.1016/S2213-2600(20)30079-5
[11]	Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708–1720. doi: 10.1056/NEJMoa2002032
[12]	Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease[J]. Chin Med J (Engl), 2020, 133(9): 1032–1038. doi: 10.1097/CM9.0000000000000775
[13]	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603–605. doi: 10.1007/s10654-010-9491-z